Research Article
Comparing Long-Term Outcomes of Entecavir and Tenofovir Disoproxil Fumarate in Liver Transplant Patients
Table 3
Baseline characteristics of recipients and donors after inverse probability of treatment weighting.
| | Variable | EVT () | TDF () | SD | value |
| | Recipient age (years) | | | 0.04 | 0.701 | | Recipient gender (, % female) | 13.6% | 13.8% | 0.01 | 0.961 | | Recipient BMI (kg/m2) | | | 0.07 | 0.521 | | Recipient HCC (, %) | 4.59% | 46.8% | 0.02 | 0.853 | | Hypertension (, %) | 14.1% | 14.7% | 0.02 | 0.878 | | Diabetes mellitus (, %) | 16.2% | 17.9% | 0.04 | 0.668 | | MELD at transplantation | | | 0.00 | 0.992 | | Baseline eGFR (mL/min/1.73 m2) | | | 0.09 | 0.381 | | HBsAg (log10 U/mL) | | | 0.08 | 0.443 | | HBV DNA detectable | 42.8% | 44.2% | 0.03 | 0.780 | | Donor age (years) | | | 0.05 | 0.621 | | Donor gender (n, % female) | 15.8% | 17.8% | 0.05 | 0.604 | | Donor BMI (kg/m2) | | | 0.00 | 0.981 | | Cold ischemic time (hours) | | | 0.08 | 0.454 | | Duration of surgery (hours) | | | 0.05 | 0.685 | | Blood loss (100 mL) | | | 0.05 | 0.596 | | ABO incompatibility (, %) | 14.3% | 13.9% | 0.01 | 0.904 | | Recipient severe postoperative complications (, %) | 37.0% | 35.3% | 0.04 | 0.730 |
|
|
Abbreviations: ENT: entecavir; TDF: tenofovir; HBsAg: hepatitis B surface antigen; MELD: Model for End-stage Liver Disease; BMI: body mass index; HBV, hepatitis B; HCC: hepatocellular carcinoma; SD: Standardized difference; eGFR: estimated glomerular filtration rate.
|
